Shanghai, China-based company that develops novel cell therapy, Neukio Biotherapeutics, closed its Series A1 financing. The company announced the closure of the round on September 2, 2022. Neukio Biotherapeutics closed the Series A1 round at USD 50 million. CD Capital led the financing for the firm. New investors such as Alwin Capital and Surplus Capital joined in the investment. Existing shareholders such as Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital also contributed the funds.
Purpose of Investment for Neukio Biotherapeutics
The company intends to accelerate the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products.
Meanwhile, Neukio Biotherapeutics seeks to ramp up its hiring. It has plans to support team recruitment and expansion.
What the founder has to say
Dr Richard Liqun Wang, the founder, chairman and CEO of Neukio, said, “In as little as ten months since the operation of our new laboratories, not only have we completed several signalling pathway modifications and CAR designs tailored for solid tumours, but also we have made significant progress in the development of innovative manufacturing processes of NK differentiation and expansion. In today’s challenging environment of the capital market, we are honoured to have received recognition from CD Capital, Alwin Capita, Surplus Capital, and previous investors of Sherpa Healthcare Partners, Lilly Asia Ventures and IDG Capital on our R&D strategy, development capabilities and project progress. I am very grateful to all investors and to G&G Capital and Silkroad Law Firm for their support in this round of financing, and we will reward them with rapidly moving forward in the preclinical and clinical validation of our R&D platform and products. The field of cell therapy is rapidly advancing with a promising future and a huge market potential, and iPSC-CAR-NK therapy has the potential to become one of the brightest stars of next-generation cell therapy.”
What the investor has to say
CD Capital, the leading investor in this financing round, said, “The transition from traditional small molecules and antibodies to the era of cell therapy is a great leap in drug design and manufacturing capabilities of a human being. With the commercialization of autologous CAR-T cell products, more and more improvement opportunities have emerged and need to be taken urgently. In the field of cell therapy, CD Capital continues to focus on innovations and breakthroughs in allogenic products to conquer solid tumours. Neukio has been deeply committed to iPSC-CAR-NK cell therapy. Within a short time of its establishment, Neukio has built up global leading technology platforms efficiently in scientific innovation and process development, demonstrating its strong execution capability and efficiency. We hope that the company, under the leadership of Dr Wang, will adhere to pragmatism, efficiency, and innovation, leading the advancement of the industry and bringing a new generation of allogenic cell therapy products to clinical application as soon as possible for the benefit of patients.”
About the company
In June 2021, Richard Wang founded the company. Established at Simbay Park in Shanghai Pilot Free Trade Zone (China), the company is an innovative biotherapeutic company focusing on developing and commercializing next-generation immune cell therapy. The company focuses on both in-house R&D innovation as well as global collaboration with leading partners. It seeks to provide valuable clinical solutions for cancer patients worldwide.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
